SELNET ALERT 33

Dear SELNET member,

We are pleased to announce that the article “Histopathological Diagnostic Agreement Study in Bone and Soft Tissue Tumors: The SELNET Sarcoma Network Experience” has been accepted for publication in JCO Global Oncology. This multicenter study, conducted within the SELNET consortium, evaluated 347 cases of bone and soft tissue tumors and reported a diagnostic concordance rate of 85.3% (Cohen’s κ=0.84, p<0.001) between local pathologists and expert reviewers, with 19 (5.5%) only cases classified as major discordance due to their potential impact on clinical management. The main causes of discrepancies were misinterpretation of morphology, limited access to immunohistochemical markers, and lack of molecular testing. These findings underscore the value of collaborative networks like SELNET in improving diagnostic accuracy and patient care in sarcomas. Congratulations to Alberto Righi, Marco Gambarotti, Prof. Angelo Paolo Dei Tos and the entire SELNET collaborative team for this important achievement.

On the other hand, our annual meeting is approaching—a key opportunity to review ongoing activities, reflect on advances in sarcoma research, and actively contribute to both the educational program and the business meeting. We warmly encourage you to participate (ideally in person, though online access will also be available) and to invite members of your team to join. Your involvement and support in engaging your group will help enrich our discussions with diverse perspectives and strengthen the impact of our program.

Thank you for your continued dedication and commitment to SELNET’s mission.

Sincerely,
SELNET Executive Committee

You are receiving this alert as a member of SELNET (Asociación Europea y latinoamericana SELNET para la Investigación en Sarcoma).
If you do not wish to receive the alert periodically, you must unsubscribe from SELNET by communicating your decision to the following e-mail address info@selnetconsortium.org